Therapeutic Response

PD-L1 < 1% status confers therapeutic sensitivity to Nivolumab in combination with Relatlimab in patients with Melanoma.

Statements

Source and description
Opdualag (relatlimab / nivolumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized Opdualag (relatlimab / nivolumab) for the first-line treatment of adults and adolescents 12 years of age and older with advanced (unresectable or metastatic) melanoma with tumor cell PD-L1 expression < 1%.